Our study reveals the potential therapeutic role of dual inhibition of CDK4/6 and PI3K/mTOR pathways in iCCA, and proposes a new paradigm for the clinical treatment of iCCA. The gene discussed is CDK4; the disease is infantile convulsions and choreoathetosis.